#PETVW

1 month ago

PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device PetVivo Holdings (OTCQX: PETV) announced that Health Canada has formally acknowledged Spryng with OsteoCushion Technology as a veterinary medical device for use in Canada. This regulatory acknowledgement is presented as a milestone in the company’s global commercialization strategy. The company said Spryng is a veterinarian-administered intra-articular injectable to support joint health and manage lameness in companion animals and equine athletes. Commercial availability in Canada is not immediate; PetVivo cited distribution setup, Canadian-specific packaging and labeling, and other operational requirements and currently anticipates potential availability in Q2 2026. Spryng is already commercially available in the United States and via select international distributors.

#PETV #PETVW PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device

www.stocktitan.net/news/PETV/pet-vivo-holdi...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

UPDATED: PetVivo AI, Inc. Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-90% PetVivo AI (OTCQX: PETV) launched PetVivo.ai, an AI SaaS platform for veterinary practices on Nov 25, 2025, after a 50-practice beta.Key disclosed metrics: qualified leads $3 each, blended CAC $42.53 (beta), median 47 new clients per practice over six months, pricing $1,999/month, LTV/CAC 25:1, payback 1 month, and gross margins 80–90%. The company positions the product against a >$150B pet care market and 30,000 U.S. veterinary practices, citing potential SaaS multiple re‑rating if adoption scales.

#PETV #PETVW UPDATED: PetVivo AI, Inc. Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-90%

www.stocktitan.net/news/PETV/updated-pet-vi...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

PetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89% PetVivo (OTCQX: PETV) launched PetVivo.ai on November 25, 2025, an AI platform the company says reduces veterinary customer acquisition costs to $42.53 (a 50–89% reduction versus typical $80–$400) and generates qualified leads for $3 each. The platform uses nine AI agents across discovery, campaign management, engagement, analytics, content, reputation, compliance, ROI optimization and integration.Beta economics (50 practices) reported a median of 47 new clients over 6 months, $3 lead cost, 80–90% gross margins, 25:1 LTV/CAC, 1 month payback and a Professional price of $1,999/month. PetVivo projects $12M ARR (Year 1), $180M ARR (Year 3) and $360M ARR (Year 5) from target practice adoption.

#PETV #PETVW PetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89%

www.stocktitan.net/news/PETV/pet-vivo-launc...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

PetVivo Holdings Announces Digital Landia’s Publication of Technical Whitepaper Validating AgenticPet AI Framework Under Exclusive 10-Year Licensing Agreement PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc.

#PETV #PETVW PetVivo Holdings Announces Digital Landia’s Publication of Technical Whitepaper Validating AgenticPet AI Framework Under Exclusive 10-Year Licensing Agreement

www.stocktitan.net/news/PETV/pet-vivo-holdi...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

PetVivo Reports Fiscal Q2 2026 Results with Revenues up 50% PetVivo (OTCQX: PETV) reported fiscal Q2 2026 results for the quarter ended Sept 30, 2025, with revenues of $303,000, up 51% year-over-year and a record second fiscal quarter. Gross profit was $220,000 with a 72.6% gross margin. Operating loss widened to $2.1 million, and net loss increased to $3.0 million or $0.11 per share. Cash totaled $768,000 and total liabilities fell 79% to $1.1 million. Company cited product launches (PrecisePRP), distributor expansion, international entry, strategic partnerships, and AI and biomaterials collaborations as drivers of growth and future commercialization.

#PETV #PETVW PetVivo Reports Fiscal Q2 2026 Results with Revenues up 50%

www.stocktitan.net/news/PETV/pet-vivo-repor...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

PetVivo Holdings, Inc. Addresses Veterinary Industry's GEN Z Problem With Breakthrough AI License Agreement PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., an emerging biomedical device company focused on the commercialization of groundbreaking medical products for horses and

#PETV #PETVW PetVivo Holdings, Inc. Addresses Veterinary Industry's GEN Z Problem With Breakthrough AI License Agreement

www.stocktitan.net/news/PETV/pet-vivo-holdi...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID PETVW) and an emerging biomedical device company focused on the commercialization of groundbreaking medical products for horses and companion

#PETV #PETVW PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics

www.stocktitan.net/news/PETV/pet-vivo-anima...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT PetVivo Holdings (OTCQX: PETV) has successfully executed note conversion agreements with four existing shareholders, converting $2,018,155 of outstanding debt into 3,669,806 shares of common stock. The debt consisted of $1,850,000 in principal plus $168,155 in accrued interest, with conversion prices ranging from $0.50 to $0.75 per share.The converted debt proceeds were used to commercialize the company's flagship products: SPRYNG® with OsteoCushion® Technology, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. This debt elimination strengthens PetVivo's balance sheet and enables greater focus on strategic growth initiatives. [ "Elimination of over $2 million in debt from balance sheet", "Successful conversion of debt to equity strengthens financial position", "No immediate cash outlay required for debt settlement", "Demonstrates shareholder confidence through willingness to convert debt to equity" ]

#PETV #PETVW PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT

www.stocktitan.net/news/PETV/petvivo-holdin...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Veterinary Medical Device Maker PetVivo Expands Global Reach with Major UK Distribution Agreement PetVivo partners with Nupsala to distribute Spryng with OsteoCushion Technology for joint pain treatment in UK veterinary market. Sales commence September 2025.

#PETV #PETVW PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH NUPSALA LIMITED

www.stocktitan.net/news/PETV/petvivo-holdin...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

PetVivo Reports Fiscal Q1 2026 Results PetVivo Holdings (OTCQX: PETV) reported strong fiscal Q1 2026 results with revenue increasing 141% to $298,000, driven by product line expansion and distributor network growth. The company's national distributor sales surged 192% to $198,000, representing 67% of total revenues.Key operational highlights include signing a distribution agreement with Eq Especialidades for Mexico market entry, partnerships with PiezoBioMembrane for biomaterial development, and Digital Landia for AI integration. The company also secured a $4.4 million private placement and uplisted to the OTCQX Best Market.Financial metrics show a gross profit increase of 69% to $187,000, though operating loss improved 9% to $1.8 million. Cash position strengthened to $3.3 million, up from $228,000 in March 2025, while total liabilities decreased 39% to $3.1 million.

#PETV #PETVW PetVivo Reports Fiscal Q1 2026 Results

www.stocktitan.net/news/PETV/pet-vivo-repor...